Beijing Souyang Management Consulting

Shouyang Pharma is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the development of next-generation small molecule drugs for cancer and inflammatory disorders. The company's research focuses on high-potency inhibitors of kinases, including BTK, ALK, and RET, to address resistance mechanisms in existing therapies. Its lead program, SY-1530, is a potent BTK inhibitor being evaluated for various B-cell malignancies. Shouyang Pharma aims to advance its diverse pipeline through internal R&D and strategic collaborations to meet significant unmet medical needs in the global market. The company leverages its expertise in medicinal chemistry to design molecules with improved selectivity and safety profiles.